GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Other Financing

Nicox (NICXF) Other Financing : $0.00 Mil (TTM As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox Other Financing?

Nicox's Other Financing for the six months ended in Jun. 2023 was $0.00 Mil.

Nicox's Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Nicox Other Financing Historical Data

The historical data trend for Nicox's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Other Financing Chart

Nicox Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nicox Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nicox Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox Other Financing Related Terms

Thank you for viewing the detailed overview of Nicox's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox (NICXF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » Other Financing
Comparable Companies
XPAR:ALNFL XPAR:PHXM XPAR:ALVIO XPAR:ALDVI XPAR:FALG XPAR:ALPAT XPAR:ALTHX XPAR:ALTME XPAR:SIGHT XPAR:ABNX OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
ALCOX:France NXOA:Germany
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Website
https://www.nicox.com
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines

From GuruFocus

Bausch Health Announces VYZULTA� (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved in South Korea

By PRNewswire PRNewswire • 02-09-2021